aHUS digital landscape in Japan will be impacted by new entrants

The entry of new treatments for atypical hemolytic uremic syndrome (aHUS) such as Swiss pharmaceutical giants Novartis (NOVN: VX) and Roche (ROG: SIX) that have strong digital experience can alter the aHUS digital landscape dynamics in Japan, says data and analytics company GlobalData.

Atulana Dey, pharma analyst at GlobalData, comments: “The incidence of the C3 variants in Japanese aHUS patients is much higher and predominant compared to other regions and races, resulting in a positive prognosis of the disease with anti-C5 therapies.”

aHUS) is an extremely rare chronic genetic disease with very limited treatment options in Japan. Soliris (eculizumab) and Ultomiris (raviluzumab LA) from Alexion, which is now is owned by AstraZeneca (LSE: AZN), are the only therapies approved. Both therapies are targeted complement C5 inhibitors. However, ravulizumab LA is the first-in-class long-acting complement C5 inhibitor that was approved in September 2020.